- Home
- CANF vs DUO Comparison
CANF vs DUO Comparison
Compare CANF & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- DUO
- Stock Information
- Founded
- CANF 1994
- DUO 2011
- Country
- CANF Israel
- DUO China
- Employees
- CANF N/A
- DUO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- DUO Real Estate
- Sector
- CANF Health Care
- DUO Finance
- Exchange
- CANF Nasdaq
- DUO Nasdaq
- Market Cap
- CANF 14.4M
- DUO 14.6M
- IPO Year
- CANF N/A
- DUO 2019
- Fundamental
- Price
- CANF $1.48
- DUO $0.65
- Analyst Decision
- CANF Strong Buy
- DUO
- Analyst Count
- CANF 2
- DUO 0
- Target Price
- CANF $14.00
- DUO N/A
- AVG Volume (30 Days)
- CANF 1.2M
- DUO 17.4M
- Earning Date
- CANF 12-31-2024
- DUO 08-30-2024
- Dividend Yield
- CANF N/A
- DUO N/A
- EPS Growth
- CANF N/A
- DUO N/A
- EPS
- CANF N/A
- DUO N/A
- Revenue
- CANF $667,000.00
- DUO $37,352,654.00
- Revenue This Year
- CANF $409.56
- DUO N/A
- Revenue Next Year
- CANF N/A
- DUO N/A
- P/E Ratio
- CANF N/A
- DUO N/A
- Revenue Growth
- CANF N/A
- DUO 6.61
- 52 Week Low
- CANF $1.29
- DUO $0.32
- 52 Week High
- CANF $4.69
- DUO $4.67
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- DUO 44.53
- Support Level
- CANF $1.30
- DUO $0.67
- Resistance Level
- CANF $1.72
- DUO $0.81
- Average True Range (ATR)
- CANF 0.18
- DUO 0.14
- MACD
- CANF -0.01
- DUO 0.02
- Stochastic Oscillator
- CANF 17.92
- DUO 11.77
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.